Wan XM, et al. - Via performing this cost-effectiveness data analysis from the CheckMate 214 randomized clinical trial, researchers investigated the cost efficacy of nivolumab plus ipilimumab as first-line treatment of metastatic renal cell carcinoma from the perspective of a US payer. Using nivolumab plus ipilimumab led to the incremental quality-adjusted life-years (QALYs) of 0.96 years vs sunitinib, at a cost of $108 363 per QALY. This study suggests nivolumab plus ipilimumab as cost-effective compared with sunitinib for intermediate- and poor-risk patients with metastatic renal cell carcinoma at a willingness-to-pay threshold of $100 000 to $150 000 per QALY.